Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:354 vs ALVO, PAHC, BIOA: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (FRA:354) has a Buyback Yield % of 0.00 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Collegium Pharmaceutical and its competitors. According to the industry distribution chart, Collegium Pharmaceutical ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Collegium Pharmaceutical's Buyback Yield % too high?
Collegium Pharmaceutical's current Buyback Yield % is 0.00. Based on the distribution chart, Collegium Pharmaceutical ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Collegium Pharmaceutical has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Buyback Yield % compare to ALVO and PAHC?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #999999 out of 290 companies for Buyback Yield %. This places Collegium Pharmaceutical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Collegium Pharmaceutical and its competitors. Collegium Pharmaceutical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Collegium Pharmaceutical (FRA:354) has a current Buyback Yield % of 0.00. The stock's GF Value™ is €35.33, compared to a current price of €30.20 — trading 14.5% below its estimated fair value. The current Buyback Yield % is 0.00. Collegium Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of €30.20 is trading 14.5% below its estimated GF Value™ of €35.33.
Key valuation signals for FRA:354:
Buyback Yield %: 0.00
GF Value™: €35.33 vs. price of €30.20 (14.5% below fair value)
No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
76GF Score
Get the complete analysis for FRA:354
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:354 has been successfully added to your 
